WVE earnings analysis
What we found in WVE's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Wave Life Sciences (WVE) reported a challenging financial year ended December 31, 2025, marked by a significant cash balance of $602.1 million and notable clinical milestones across multiple product candidates. Despite this, the company remains unprofitable with persistent operating losses and a diluted EPS of -0.29 in Q4 2025, leading analysts to maintain a cautious outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Cash Position
- Wave ended 2025 with $602.1 million in cash and cash equivalents, ensuring operational runway until mid-2028.
- Clinical Milestones Achieved
- In 2025, the company advanced its R&D pipeline, including key data in its WVE-007 trial for obesity and generated $80.9 million in revenue from the GSK collaboration.
- Narrowed Annual Loss
- The net loss for Q4 2025 was reported at $17 million, down from a loss of $26 million in Q4 2024.
- Strong Clinical Data
- Presented positive interim data for WVE-007, catalyzing the largest financing in Wave’s history, raising $402.5 million.
- Increased Equity Grants to Executives
- For 2026, executive equity awards included options priced at $12.75, valuing compensation at market-driven levels.
- GSK Partnership Solidified
- The collaboration with GSK resulted in an upfront cash payment of $120 million and additional milestones.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Unprofitability
- Wave has sustained operating losses with a reported net loss of $17 million in Q4 2025, raising concerns about long-term viability.
- Heavy Reliance on External Collaboration
- Dependence on GSK collaboration for revenue may expose the company to risks related to partnership dynamics.
- Regulatory and Clinical Trial Risks
- Ongoing clinical trials and regulatory feedback for several programs may face delays or setbacks, impacting future revenue forecasts.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.27
- Gross margin
- 100%
- Operating margin
- 27.4%
What they said about what is next.
Management has not provided numeric full-year guidance, focusing on program milestones and operational execution.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 28, 2026
- Wave Life’s Q1 2026 report shows meaningful clinical progress and a narrower GAAP loss: net loss for the quarter was $26.1 million versus $46.9 million a year earlier, while reported collaboration revenue was material.…
- 10-K · February 26, 2026
- Wave Life Sciences (WVE) positions itself as a multimodal RNA medicines company (PRISM®) focused on hepatic/metabolic and rare disease programs (WVE-007, WVE-006, WVE-008 plus DMD and HD programs). The filing highlights…
- 10-Q · November 10, 2025
- Wave reported Q3 2025 revenue of $7.608M (turning positive from $(7.676)M in Q3 2024) and a GAAP loss per share of $(0.32), improved versus $(0.47) a year ago. Operating loss narrowed to $56.353M from $63.915M…
- 10-Q · May 8, 2025
- Wave reported Q1 revenue of $9.175M and GAAP net loss of $46.878M (EPS -$0.29), missing revenue and EPS consensus. R&D and G&A rose to $40.622M and $18.357M respectively, driving an operating loss of $49.804M. Cash…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing WVE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever